This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

EMD 273063

Merck KGaA

Drug Names(s): hu14.18-IL2 fusion protein

Deal Structure: EMD 273063 (hu14.18-IL2) binds to ganglioside GD-2 to trigger an immune response. GD-2 is a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues, principally to the cerebellum and peripheral nerves in humans. The relatively tumor specific expression of GD-2 makes it a suitable target for immunotherapy with monoclonal antibodies or with artificial T cell receptors.

EMD 273063 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug